Clinical Trial Detail

NCT ID NCT04383938
Title Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Aprea Therapeutics
Indications

transitional cell carcinoma

Advanced Solid Tumor

bladder urothelial carcinoma

stomach cancer

lung non-small cell carcinoma

gastroesophageal junction adenocarcinoma

Therapies

APR-246 + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.